Glioblastomas account for approximately 20% of all primary brain tumors in adults. Glioblastoma multiforme (GBM) is a highly malignant tumor. In spite of advances in surgery, chemotherapy, and radiotherapy, the life expectancy of the patient with glioblastoma is approximately 11 months. To enhance glioma-specific gene delivery, we employed a 12-mer phage display peptide library to isolate phages that bind specifically to human glioma cell lines. Here, we report the isolation and functional characterization of novel glioma-specific peptides that target transgenes specifically to a wide array of human glioblastomas in vitro and in vivo. One of the isolated peptides, tentatively denoted as MG11, is demonstrated to be glioma specific and gives an in vitro-binding enrichment of more than 5-fold for glioma cells when compared with nonglioma cells. Intravenous injection of phages bearing the MG11 peptide-binding motif enables the phages to home specifically to glioma xenografts. Most significantly, when Lissamine rhodamine-labeled MG11 peptide is injected intratumorally, it targets specifically to glioma xenografts instead of non-glioma-derived xenografts. In summary, our results suggest that the MG11 peptide is able to target specifically to tumors of glial origin, which would allow the design of applications related to the diagnosis and treatment of human gliomas.
INTRODUCTION I
DENTIFICATION OF MOLECULES that mediate the targeted delivery of therapeutic DNA or drugs to specific cell types can significantly reduce the amount of therapeutic agent required, and would therefore reduce the potential toxicity to nontarget cells. Glioblastoma multiforme (GBM) is a highly malignant tumor and accounts for more than 20% of primary brain tumors in adults. In spite of advances in surgery, chemotherapy, and radiotherapy, the life expectancy of patient with glioblastoma is approximately 11 months (Cowan et al., 2000) . A prominent clinical feature of GBM is its ability to infiltrate into surrounding brain tissues, thus rendering complete surgical removal practically impossible. One way to overcome this difficulty is to design strategies that facilitate the delivery of therapeutic agents specifically to glioma cells.
One of the common methods to enable gene expression in a selected cell population is to incorporate gene expression cassettes under the control of a tissue-specific promoter (Shibata et al., 2000; Ueno et al., 2001) . Tissue-specific promoters are generally linked with weak induction of transgene expression, and rely on inducible agents that might exert unfavorable effects on the host (Agha-Mohammadi and Lotze, 2000; Nettelbeck et al., 2000) . Moreover, the essential upstream control re-gion that regulates gene expression from a particular promoter can span more than a few kilobases. Cloning the whole region would be difficult in the construction of transcriptionally mediated targeted vector systems (Agha-Mohammadi and Lotze, 2000; Nettelbeck et al., 2000) .
There has been much progress in the study of vector targeting by means of various vector systems. Wu and Wu (1987) were the first to report the use of the glycoprotein asialoorosomucoid (ASOR) to specifically target the liver parenchyma. Retroviral vectors have been modified to present a chimeric envelope that targets to breast cancer cells (Tai et al., 2003) . About 50% of GBM tumors show amplification or mutations that activate the gene encoding the epidermal growth factor receptor (EGFR), thus producing a constitutively active receptor in the absence of the EGF ligand (Mischel and Cloughesy, 2003) . Vectors that target to this growth factor receptor have been designed. Doubly ablated adenoviral vectors, lacking both the coxsackievirus-adenovirus receptor (CAR)-and ␣ v -integrin-binding capacities, together with bispecific single-chain antibodies that recognize both the EGFR and the epithelial cell adhesion molecule, have been employed for specific gene delivery to primary human brain tumors (van Beusechem et al., 2002; Samoylova et al., 2003) . Fusion proteins consisting of peptide toxins fused to the human EGF (DAB389EGF) has been demonstrated to selectively kill cells that overexpress EGFR (Cohen et al., 2003) .
Phage display techniques have been used for selection of whole cells to identify peptide ligands directed against particular cell surface proteins (Parmley and Smith, 1988; Barry et al., 1996; Szardenings et al., 1997; Campa et al., 2002; . Using this technique, peptides that bind to kidney, lung, skin, pancreas, intestine, uterus, adrenal gland, retina, fibroblast cells, myoblasts, myotubes, human neutrophils, human laryngeal carcinoma cells, endothelial cells (Barry et al., 1996; Arap et al., 1998; Koivunen et al., 1999; Pasqualini et al., 2000; White et al., 2001) , and a human colorectal cell line (Rasmussen et al., 2002) have been identified. Peptides that home selectively to the vasculature of various organs were isolated by the in vivo biopanning of peptide phage display libraries in mice (Pasqualini and Ruoslahti, 1996; Rajotte et al., 1998; Arap et al., 2002a; Essler and Ruoslahti, 2002; Trepel et al., 2002) , as well as in humans (Arap et al., 2002b) . The selected sequence can be used to target therapeutic agents and diagnostic imaging radiolabels (Schumacher et al., 2002) .
In this study, we describe the isolation and characterization of a novel peptide, MG11, using phage display technology. This peptide targets specifically, both in vitro and in vivo, to human glioma xenografts.
MATERIALS AND METHODS

Cell lines
dGli36 cells (gift from M. Sena-Esteves, Children's Hospital of Philadelphia, Philadelphia, PA), which overexpress a truncated mutant EGFR commonly found in human gliomas, were grown in the presence of puromycin (1 g/ml; Sigma-Aldrich, St. Louis, MO). SF767 and U251MG human gliomas were kindly provided by D.F. Deen (Brain Tumor Research Center, UCSF School of Medicine, San Francisco, CA). CNE2 cells are derived from undifferentiated human nasopharyngeal carcinoma (gift from H.M. Wang, Cancer Institute, Guangzhou, People's Republic of China). All human tumor cell lines-A549 (lung adenocarcinoma), CNE2 (nasopharyngeal carcinoma), HeLa (cervical carcinoma), HepG2 (hepatoma), HK1 (nasopharyngeal carcinoma), KOSC-3 (head and neck carcinoma), KZ2 (melanoma), M059K (glioblastoma), SF767 (glioblastoma), T98G (glioblastoma), U87MG (glioblastoma), U251MG (glioblastoma), U373MG (anaplastic astrocytoma), and WT18 (lymphoma)-used in this study were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS; HyClone Laboratories, Logan, UT), penicillin (100 U/ml; Invitrogen, Grand Island, NY), streptomycin (100 g/ml; Invitrogen), and 2 mM L-glutamine (SigmaAldrich). Normal human astrocytes purchased from Cambrex Bio Science Walkersville (Walkersville, MD) were cultured in astrocyte basal medium supplemented with recombinant human EGF, insulin, ascorbic acid, GA-100, L-glutamine, and FBS as recommended by the supplier (Cambrex Bio Science Walkersville).
Primary glioma cell culture
A single primary glioma biopsy was kindly provided by J. Thomas (Department of Neurosurgery, Singapore General Hospital, Singapore) with the patient's consent. Tissues were immediately kept in DMEM with 10% FBS. To obtain a singlecell suspension, the tissues were digested for 5 min with 0.25% trypsin, followed by washing twice with complete DMEM. The cells were plated into a single well of a 96-well plate (Nunc, Roskilde, Denmark), and incubated at 37°C in a humidified incubator with 5% CO 2 for 24 hr before being assayed for the binding of the MG11 peptide.
Phage display library biopanning
The phage display library employed for biopanning for glioma-specific phage was the Ph.D.-12 library (New England BioLabs, Beverly, MA). Phage was selected for binding to human glioma cell line by panning against intact cells in suspension. Glioma cell lines (dGli36, SF767, U87MG, U251MG, and U373MG) were grown in monolayer until confluent, and harvested by treating the cell with phosphate-buffered saline (PBS) containing 5 mM EDTA. The five glioma cell lines were mixed together in equal proportions to give a final cell number of 1 ϫ 10 6 . This was followed by incubating the cell mixture with 1 ϫ 10 11 plaque-forming units (PFU) of M13 phage at 37°C for 2 hr. The cells were washed once with PBS containing 0.1% Tween 20 and nine times with PBS, followed by pelleting and resuspension to remove unbound phage. Bound phage were recovered by eluting with 0.2 M glycine, pH 2.2, containing bovine serum albumin (BSA, 1 mg/ml; Sigma-Aldrich), followed by neutralization with 1 M Tris-HCl (pH 9.1). Recovered phages were amplified in ER2537 bacteria (New England BioLabs) and subjected to two additional rounds of enrichment panning. These enrichment pannings were then followed by three rounds of subtraction panning against A549, CNE2, and HepG2 successively. The isolated phage clones were titered using ER2537 bacteria.
To determine the in vitro specificity of the recovered phages to glioma and nonglioma cell lines, 1 ϫ 10 6 cells were incubated with 10 12 PFU of the isolated phage clone at 37°C for 2 hr. Unbound phage were removed and bound phage were recovered and titered as mentioned.
Amplification of phage clones
ER2537 bacteria were employed for phage amplification. To 20 ml of log-phase bacteria culture, 1 ϫ 10 10 PFU of the phage was added and the mixture was incubated for 4.5 hr at 37°C in a shaking incubator. To precipitate the phages, a 1/6 volume of PEG 8000-NaCl solution was added to the bacteria-phage mixture and precipitated at 4°C overnight. The next day, phage were harvested by centrifugation at 13,000 rpm for 10 min at 4°C. The resulting phage pellet was resuspended in 1 ml of Trisbuffered saline (TBS). The phage were further precipitated by adding a 1/6 volume of the PEG-NaCl solution. After incubating for 1 hr on ice, the phage were pelleted at 13,000 ϫ g for 10 min at 4°C and resuspended in 200 l of TBS containing 0.01% sodium azide. The amplified phage were titered and stored at 4°C.
Titering of phage
To determine the titer, amplified phage were serially diluted in Luria broth (LB). Each of the diluted phage solutions was added to a log culture of ER2537 bacteria. After incubating for 5 min at room temperature to allow infection to take place, 3 ml of melted 0.7% agarose (45°C) was added and the mixture was poured onto an LB agar plate containing 5-bromo-4-chloro-3-indolyl-␤-D-galactoside (X-Gal, 40 mg/ml; Bio-Rad, Hercules, CA), and isopropyl ␤-D-thiogalactoside (IPTG, 50 mg/ml; Invitrogen). The titer of the phage solution was determined by counting the number of blue plaques after 24 hr of incubation.
In vivo targeting of phage to tumor xenograft
Six-week-old female nude mice were purchased from the Animal Resource Center (Animal Resource Centre, Perth, Australia). dGli36 cells (2 ϫ 10 6 ) suspended in 10 l of PBS were stereotactically inoculated into the bregma region (2 mm lateral, 0.25 mm depth) of the right hemisphere of the mice. Tumor growth was monitored by magnetic resonance imaging (MRI), hematoxylin and eosin (H&E) staining, and loss of body weight. Phage was injected via the tail vein 10 days postinoculation of tumor cells, when the tumor volume was approximately 75 mm 3 .
For subcutaneous tumors, 5 ϫ 10 6 SF767 or dGli36 glioma cells and CNE2 (nonglioma cells control) were suspended in 100 l of PBS and injected into the right and left flanks of 6-week-old SCID mice (Animal Resource Centre), respectively. Tumor growth was monitored by measuring the tumor volume. The tumor volume was calculated according to the following formula: tumor volume (mm 3 ) ϭ 0.52 ϫ (width [mm 2 ] ϫ length [mm]) (Bergers et al., 1999) . Phage was injected via the tail vein 7 days postimplantation of tumor, when the tumor volume was approximately 100 mm 3 .
Tumor-bearing mice were randomized into two groups (five per group), namely the control group and the experimental group. Either control phage or phage bearing the MG11 sequence (1 ϫ 10 12 PFU), suspended in 400 l of DMEM, was injected via the tail vein into tumor-bearing mice, and allowed to circulate for 24 hr. After 24 hr, mice were anesthetized and perfused through the heart with DMEM. Tumor and other organs were dissected and weighed. The tissues were homogenized in ice-cold DMEM containing protease inhibitor cocktail and 0.1% BSA. After centrifugation to remove the tissue debris, bound phages were rescued by mixing the supernatant with 0.5 ml of ER2537 bacteria (New England BioLabs) for 30 min at 37°C. The supernatant containing phage was diluted in LB, after which aliquots were plated on LB agar plates containing X-Gal and IPTG. As control, unselected phage was administered at the same titer in the second group of animals.
Peptides
Poly-L-lysine-SIPVKFNKP-MG11 [(K 16 )-MG11] and poly-L-lysine-SIPVKFNKP-H42 [(K 16 )-H42] peptides were synthesized and purified (Mimotopes, Victoria, Australia). The peptides were dissolved in 0.15 M NaCl at 1 mg/ml and stored in small aliquots at Ϫ20°C. The purity of both peptides was Ͼ90%.
Formation of peptide-DNA complexes
The formation and transfection of peptide-DNA complexes were carried out according to Patel et al. (2001) with slight modifications. Peptide-DNA complexes were prepared at a peptide:DNA ratio of 2:1 (w/w). Plasmid DNA was diluted to 10 g/ml in Ringer's buffer (B. Braun Melsungen, Melsungen, Germany). The appropriate volume of peptide was also diluted in Ringer's buffer to give a final concentration of 20 g/ml (peptide:DNA ratio, 2:1). The peptide was added dropwise to the DNA solution while vortexing gently. This mixture was allowed to incubate at room temperature for 30 min. After 30 min, the mixture was diluted to 4 g of DNA per milliliter with DMEM in the presence of 100 M chloroquine, and added to cells.
Transfection of tumor cell lines
For transfection, 3 ϫ 10 5 cells were seeded into each well of a six-well plate (Nunc). After culturing the cells overnight, the cells were washed twice with PBS. Freshly prepared peptide-DNA complexes were added to each well and incubated for 2 hr at 37°C. For transfection performed in the presence of serum, FBS was added to a final concentration of 10% immediately after the addition of peptide-DNA complexes. Reporter gene activity was assayed after 24 or 48 hr.
Assay for luciferase activity
Cells were harvested from six-well plates 24 or 48 hr after transfection, washed, resuspended in 120 l of Tris-HCl (pH 7.8), and freeze-thawed three times. Cell debris was discarded after centrifugation at 14,000 ϫ g at 4°C for 10 min. One hundred microliters of the supernatant collected was used for assaying luciferase activity, using the Auto-Lumat LB952 luminometer (Berthold Technologies, Bad Wildbad, Germany). Five microliters of the supernatant collected was used for the determination of protein concentration, using the Bio-Rad protein assay dye reagent with an Ultrospec 3000 UV/visible spectrophotometer (Amersham Biosciences, Uppsala, Sweden).
In vitro fluorescent peptide-binding assay
For the in vitro binding assay, 1 ϫ 10 5 cells were seeded into each well of a 24-well dish (Nunc). After culturing the cells overnight at 37°C, the cells were washed once with PBS, followed by incubation in blocking buffer containing PBS with 1% BSA at room temperature for 1 hr. The cells were washed twice with PBS. One hundred nanograms of Lissamine rhodamine-conjugated (K 16 )-MG11 peptide (Mimotopes) was added to the blocking buffer containing 0.1% sodium azide, and incubated with the cells at 37°C for 20 min. This is followed by five washes with PBS with 0.1% Tween 20 at room temperature at 5-min intervals. The cells were then fixed in 4% paraformaldehyde. After removal of excess paraformaldehyde, the cells were mounted. Images were captured digitally and analyzed with an LSM 510 Meta confocal microscope (Carl Zeiss, Göttingen, Germany) with appropriate filters.
In vivo fluorescent peptide-binding assay SF767 tumor-bearing mice were randomized into two groups (two per group). Fifty microliters containing 100 g of Lissamine rhodamine-conjugated (K 16 )-MG11 or (K 16 )-H42 was injected intratumorally into each of two mice harboring the tumor, and allowed to circulate for 20 min. After 20 min, the mice were anesthetized and perfused through the heart with PBS followed by 4% paraformaldehyde. The tumor were dissected and cryosectioned. The sections were then counterstained with fluorescein isothiocyanate (FITC)-phalloidin and mounted. Images were examined with the LSM 510 Meta confocal microscope (Carl Zeiss) with the appropriate filters.
Statistical analysis
Data are presented throughout this study as means Ϯ standard error of the mean. Statistical significance was evaluated by paired t test, and p Ͻ 0.05 was considered significant.
RESULTS
Enrichment of glioma-specific phage by in vitro biopanning
The Ph.D-12 phage display library, with a complexity of approximately 2 ϫ 10 9 sequences, was employed for screening peptides that would bind specifically to human glioma cells. This library consists of 12-mer peptide sequences fused to the N terminus of the minor coat protein of the M13 phage, in a valency of 5 copies per virion. The library was screened against a mixture of human glioma cell lines including dGli36, SF767, U87MG, U251MG, and U373MG at 37°C to increase the probability of obtaining sequences that could interact generically with most glioma cells. Phages rescued were further subjected to negative panning with nonglioma cell lines A549, CNE2, and HepG2, to eliminate nonspecific background binding. The amino acid sequences of the 79 phage clones obtained after such a selection revealed several dominant sequence motifs (Table  1) . The sequence SGHQLLLNKMPN, designated MG2, was found in 24% of the clones; and LWATFPPRPPWL, designated MG11, was found in 19% of the clones (Table 1) . A BLAST search of MG2 demonstrated 60% sequence homology with the human mitogen-activated protein kinase kinase kinase 12 (MAP3K12). MAP3K12 was found to be highly expressed in brain and kidney, and has been implicated as an activator of the JNK-SAPK pathway (Su and Karin, 1996) . Analysis of the second most frequently isolated phage-bearing peptide sequence, designated MG11, showed it to be 64% homologous to semaphorin 4B precursor protein. Semaphorin 4B is a member of the semaphorin superfamily, which is involved in the inhibition of axonal extension by providing local signals to specify territories inaccessible to growing axons (Rieger et al., 2003) . In addition to phage bearing the MG11 peptide sequence, we have also isolated two other phage clones harboring peptide sequences that match the semaphorin family of proteins. One of the sequences, HHGHSPTSPQVR, matches perfectly the protein sequence of semaphorin 3A precursor protein, whereas the other peptide sequence, LPYGTSNRHAPV, showed 64% homology with semaphorin 6B precursor protein. Semaphorin 3A, which binds with high affinity to neuropilin 1, induces the collapse and paralysis of neuronal growth cones. Neuropilin 1 is a receptor for the vascular endothelial growth factor family and has been implicated in blood vessel formation. It also functions as a coreceptor with the Flk-1/KDR receptor tyrosine kinase (Gluzman-Poltorak et al., 2000) . We noticed that several groups of the peptides selected are homologous to members of the semaphorin superfamily. It has been previously reported that semaphorin family proteins play important roles during neural development (Schumacher et al., 2002; Rieger et al., 2003) . Because MG11 is the most common sequence identified among the group of phages isolated, MG11 was thus chosen for subsequent studies.
Characterization of the binding epitopes of MG11 phage
To determine whether MG11 phage binds specifically to glioma cells, tumor cell lines of various histotypes were incubated with the phage. These included dGli36, SF767, U87MG, U251MG, U373MG, and T98G glioma cells and A549, CNE2, HeLa, HepG2, KOSC-3, KZ2, and WT18 nonglioma cells as shown in Fig. 1 . The efficiency of MG11 phage binding to glioma cells (range, from 2 ϫ 10 6 to 2.2 ϫ 10 7 PFU/ml) was at least 3-fold higher than that of nonglioma cells (Fig. 1) . None of the nonglioma origin tumor cell lines tested exhibited considerable binding (range, from 1.5 ϫ 10 4 to 9.6 ϫ 10 5 PFU/ml). Thus, the in vitro phage-binding assay indicated that MG11 phage binds specifically to glioma cells.
To determine whether phage bearing the MG11-binding motif can target specifically in vivo to human glioma xenografts, 10 12 PFU of MG11 phage was injected via the tail vein to immunodeficient SCID mice harboring subcutaneous dGli36-derived glioma xenografts. Recovery of phage particles from tissues as well as xenografted dGli36 tumor indicated that MG11 phage is specific for tumor only (7.94 ϫ 10 4 PFU/mg), whereas other tissues including brain, heart, kidney, liver, lung, and spleen gave only background binding ( Fig. 2A) . Minimal binding was observed in all tissues when control unselected phage was employed (Fig. 2A) . The tumor specificity of MG11 was also examined by administering MG11 phage via the tail vein to immunodeficient mice bearing subcutaneous glioma xenograft (dGli36) and nonglioma xenograft (CNE2) on the right and left hind thigh, respectively. The enrichment factor in homing to the subcutaneous dGli36 glioma xenograft (7.9 ϫ 10 4 PFU/mg), compared with the subcutaneous CNE2 tumor (1.67 ϫ 10 4 PFU/mg), was 5-fold, (p ϭ 0.03) (Fig. 2B, part i) . Similar results were obtained when another human glioma, SF767, was used. The enrichment factor in homing of MG11 phage to SF767-derived tumor (8.34 ϫ 10 3 PFU/mg) was 4-fold higher when compared with CNE2-derived tumor (2.21 ϫ 10 3 PFU/mg) (p ϭ 0.02) (Fig. 2B, part ii) , indicating that the binding of MG11 to human glioma cell lines is specific.
The specificity of MG11 phage binding to human glioma cells in the context of normal mouse astrocytes was investigated. Phage (10 12 ) were injected via the tail vein into immunodeficient nude mice bearing an intracranial xenograft of dGli36 human glioma cells in the right hemisphere. Phage recovered from the right hemisphere bearing the xenografted tumor (9.2 ϫ 10 2 PFU/mg) in mice injected with the MG11 phage gave an enrichment of 20-fold compared with those recovered from the normal side of the brain (0.5 ϫ 10 2 PFU/mg) (left hemisphere) (p ϭ 0.013) (Fig. 2C) . No significant difference could be detected in the control groups injected with unselected phage (Fig. 2C) . These results demonstrated that phage bearing the MG11 epitope target specifically to cells of glial origin and do not bind to normal brain cells.
In vitro specificity of (K 16 )-MG11 in human tumor cell lines
The amino acid residues that make up the MG11 peptide sequence are hydrophobic and could not be easily purified. To facilitate the purification procedure, we have inserted 16 lysine residues into the sequence. The addition of polylysine residues has been demonstrated to enhance the potential of the peptide to interact with the negatively charged plasmid DNA as demonstrated by Patel et al. (2001) . In addition to the polylysine residues, a spacer sequence identical to that used by Patel et al. was also included to facilitate the movement of the peptide.
The (K 16 )-MG11 peptide was chemically synthesized and complexed with a luciferase reporter plasmid, pNGVL-Luciferase (pNGVL-Luc). To determine the optimal concentration that would allow DNA and peptide interactions, and to maximize the efficiency of gene uptake, various peptide:DNA ratios were used in the transfection of SF767 cells.
Various ratios of the pNGVL-Luc plasmid and (K 16 )-MG11 peptide were complexed, followed by incubation in SF767 glioma cells in the presence of chloroquine. Chloroquine was added as it has been previously demonstrated to prevent lysosomal DNA degradation (Zauner et al., 1997) . After 24 hr, luciferase expression was detected at a peptide:DNA ratio (w/w) of 2:1 (39,803 RLU/g protein) (Fig. 3A, part i) . The level of luciferase expression increased with escalating ratios of peptide to DNA (Fig. 3A, part i) . This suggests that the abundance of lysine residues could facilitate the interaction of the peptide with the DNA molecules, hence ensuring that the majority of the DNA molecules are complexed with the peptide. At peptide:DNA ratios of 10:1 and 20:1, toxicity could be detected as the treated SF767 glioma cells were not as healthy as the untreated controls. This could be due to the presence of the high concentration of polylysine, which is known to be toxic to cells (Zauner et al., 1997) . For subsequent experiments, we therefore adopted the optimal peptide:DNA ratio of 2:1.
To rule out the possibility that the binding of the peptide to the cells is due to the lysine residues inserted, we synthesized a control peptide in our experiment to confirm that the luciferase activities observed were a consequence of targeting. A control peptide, comprising the 16-lysine residue followed by a 12-amino acid sequence derived from biopanning of a nonglioma cell line, (K 16 )-H42, was also synthesized. H42 bears the sequence GGPTKEWELYLF. Similar experiments were carried out with the luciferase DNA and (K 16 )-H42 at various peptide:DNA ratios and no significant binding could be detected when analyzed 24 hr posttransfection (Fig. 3A, part ii) .
To further demonstrate the specificity of (K 16 )-MG11 peptide for glioma cells and to determine the optimal time point of luciferase transgene expression, peptide-DNA complex, prepared by mixing (K 16 )-MG11 peptide with pNGVL-Luc DNA at a 2:1 (w/w) ratio, was added to tumor cell lines of various histotypes. These included dGli36, SF767, U251MG, U373MG,
FIG. 4.
In vitro specificity of Lissamine rhodamine-labeled (K 16 )-MG11 peptide. Tumor cell lines of various origins were incubated with 100 ng of (K 16 )-MG11 peptide for 20 min at 37°C. Cells were subsequently fixed and mounted as described in Materials and Methods. Fluorescence images were studied with an LSM 510 Meta confocal microscopy system.
FIG. 5.
Binding of Lissamine rhodamine-labeled (K 16 )-MG11 peptide to primary human glioma culture. Primary human glioma culture (A), SF767 human glioma cells (B), and normal human astrocytes (C) were incubated with 100 ng of (K 16 )-MG11 for 20 min at 37°C. Cells were subsequently fixed and mounted as described in Materials and Methods. Fluorescence images were studied with an LSM 510 Meta confocal microscopy system. A549, HeLa, HepG2, and CNE2 cells. Binding of peptide-DNA complexes was performed in the presence of 100 M chloroquine, and luciferase expression was assayed 24 and 48 hr after transfection. Luciferase activity in the SF767 glioma cell line (85,473 RLU/g) was at least 4-fold higher than in the CNE2 cell line (19,849 RLU/g) 24 hr posttransfection. The level of gene expression 48 hr postdelivery is much higher than that at 24 hr (Fig. 3B, part i) . The level of luciferase expression detected in U251MG, dGli36, and SF767 glioma cell lines increased dramatically by 48 hr after transfection (Fig. 3B, part  i) . Experiments using (K 16 )-MG11 peptide complexed with the reporter gene encoding enhanced green fluorescent protein (eGFP) also gave similar results (Fig. 3B, part ii) . Strong green fluorescence could be detected in U251MG glioma cells but not in HepG2 human hepatocellular carcinoma cells. Furthermore, when peptide-DNA complexes prepared from (K 16 )-MG11 or (K 16 )-H42 peptide with pNGVL-Luc were mixed and added to SF767 and CNE2 cells, the luciferase expression in SF767 glioma cells transfected with (K 16 )-MG11:pNGVL-Luc (716,940 RLU/g) was 84-fold higher than that of (K 16 )-H42:pNGVL-Luc (8444 RLU/g) control peptidetransfected cells. The results thus demonstrate that the binding of (K 16 )-MG11 peptide is specific, and not due to the presence of positively charge lysine residues (Fig. 3C ). When compared with the CNE2 nonglioma cell line, the level of luciferase expression observed in SF767 glioma cells transfected with pNGVL-Luc:(K 16 )-MG11 is 151-fold higher (Fig. 3C) . These results clearly illustrate that (K 16 )-MG11 is specific for glioma cells.
Characterization of (K 16 )-MG11 peptide-targeted delivery in vitro and in vivo
To determine the direct specific binding of (K 16 )-MG11 peptide to the cell surface of glioma cells, (K 16 )-MG11 peptide was conjugated to Lissamine rhodamine. After incubating the various tumor cell lines (SF767, U251MG, M059K, A549, HepG2, and HK1) with Lissamine rhodamine-conjugated (K 16 )-MG11 peptide, the cells were examined by confocal microscopy and the levels of fluorescence detected were compared. SF767, U251MG, and M059K human glioma cell lines exhibited detectable fluorescence as shown by the presence of rhodamine on the surface of the cells (Fig. 4, top) . Little or no fluorescence was observed with nonglioma cell lines (Fig. 4, bottom) . In contrast, nonspecific red fluorescence was observed in all cell lines studied when incubated with (K 16 )-H42 control peptide under similar conditions (data not shown). Unlike the (K 16 )-MG11 peptide, no discrimination between glioma and nonglioma cells could be ascertained with the rhodamine-conjugated (K 16 )-H42 peptide (data not shown).
The binding specificity of (K 16 )-MG11 peptide to primary human glioma cells and normal primary human astrocytes was subsequently determined. Primary human glioma cells derived from biopsy or normal primary human astrocytes were incubated with Lissamine rhodamine-conjugated (K 16 )-MG11 peptide at 37°C for 20 min. Significant binding of the (K 16 )-MG11 peptide was observed only in primary human glioma cells (Fig.  5A ). This binding specificity is comparable to that observed in the SF767 human glioma cell line (Fig. 5B) . In contrast, no fluorescence could be detected with normal primary human astrocytes under similar conditions (Fig. 5C) . These results clearly demonstrated that the MG11 peptide is specific for human glioma cells and does not bind to normal human astrocytes.
To further demonstrate the tumor specificity of the (K 16 )-MG11 peptide for glioma xenografts, SCID mice harboring subcutaneously established SF767-derived xenografts were injected intratumorally with Lissamine rhodamine-conjugated (K 16 )-MG11 peptide and (K 16 )-H42 peptide. After 20 min of circulation, the mouse bearing the SF767 glioma xenograft was perfused and tumor was harvested. The tumor sections were counterstained with FITC-labeled phalloidin, which stains Factin, to show the cell surface. Cryostat sections of the tumors showed red fluorescence binding in SF767 glioma xenograft injected with (K 16 )-MG11 peptide (Fig. 6A) , demonstrating the binding of (K 16 )-MG11 peptide. This binding, as observed in the inset (I), indicated that (K 16 )-MG11 peptide interacted with cell surface receptors on the tumor cells. In contrast, red fluorescence was not detected in the SF767 tumor injected with (K 16 )-H42 peptide (Fig. 6B) . Although the stainings obtained with FITC-labeled phalloidin (green) and Lissamine rhodamine-conjugated (K 16 )-MG11 peptide (red) were in close proximity, they did not colocalize. This reflects the fact that the receptors for MG11 peptide are located on the external side of the plasma membrane, whereas F-actin is situated just below this external periphery membrane layer. Taken together, our results suggested that the observed fluorescence can be attributable to the specific binding and subsequent uptake of (K 16 )-MG11 peptide.
DISCUSSION
Gene transfer to malignant gliomas has been extensively pursued both in cell culture as well as in animal model experiments. However, clinical gene therapy trials for recurrent gliomas have not fulfilled the high expectations suggested by preclinical laboratory results. One of the significant pitfalls is the low transduction efficiency of tumor cells observed in vivo, resulting in expression of therapeutic gene products at too low a level to efficiently eradicate tumor cells (Weyerbrock and Oldfield, 1999; Rainov and Kramm, 2001; Rainov and Ren, 2003) . Retrovirus vector was one of the earliest viral vectors to be employed for the delivery of therapeutic genes to gliomas in the clinical setting (Rainov and Ren, 2003) . Although both phase I and II clinical studies showed favorable safety profiles and some efficacy, the phase III study failed to demonstrate significant progression-free or extension of overall survival (Rainov and Ren, 2003) . The use of adenovirus vectors, as well as herpes simplex virus-based vectors, has also been actively pursued both in the laboratory and clinic (Bansal and Engelhard, 2000) .
A commonly employed strategy for gene delivery to the brain involved direct stereotactic injection of vectors to the coordinates of interest. Most often, this approach is limited by the volume and number of injections that one would need in order to achieve therapeutic doses. Moreover, with this route of administration, the vector is taken up only by cells in the immediate vicinity of the injection site. Improved strategies for the selective delivery of therapeutic agents are therefore needed to combat devastating and usually fatal glioblastoma multiforme tu- (K 16 )-H42 peptide (B) was injected intratumorally into separate mice bearing the SF767 human glioma xenograft and allowed to circulate for 20 min. Afterward, the tumors were harvested and cryosectioned. Fluorescence images were studied with an LSM 510 Meta confocal microscopy system. I, Insert.
mors. In this report, we have employed a phage display peptide library to isolate and characterize phages bearing peptide sequences that bind specifically to a wide array of human glioma cell lines. Analysis of the 79 phage clones obtained after biopanning of the Ph.D.-12 phage library revealed several dominant sequence motifs (Table 1) . The sequence SGHQL-LLNKMPN, encoded by the phage MG2, was found in 24% of the clones and this sequence was shown to have 60% homology with the human mitogen-activated protein kinase kinase kinase 12 (MAP3K12). The second most frequently isolated phage clone, MG11, bears the sequence LWATFPPRPPWL, which matches that of semaphorin 4B precursor, a membranebound semaphorin. Interestingly, two other phage clones that harbor peptide sequences with homology for the semaphorin family of proteins were also identified ( Table 1 ). The sequence HHGHSPTSPQVR matches the protein sequence of secreted semaphorin 3A precursor protein, whereas the sequence LPYGTSNRHAPV is homologous to that of membrane-bound semaphorin 6B precursor protein. Semaphorin 3A has been reported to bind with high affinity to neuropilin 1 (Rieger et al., 2003) , a receptor for the vascular endothelial growth factor family (Miao et al., 2000) . Neuropilin 1, together with plexin, a receptor for transmembrane-bound semaphorins (Rieger et al., 2003) , forms complexes with class 3 semaphorins that are able to direct growing axons to their targets (Tamagnone et al., 1999) . Besides modulating the extension of axonal cones, semaphorins also regulate the migration of neural progenitor cells (Marin et al., 2001) . One of the clinical features of gliomas is their ability to infiltrate and migrate to distant sites within the brain; it is therefore speculated that semaphorins could play a role in the carcinogenesis of glioma. This suggestion is consistent with reports of the presence of semaphorins in the progression of mouse mammary tumor and metastatic human lung adenocarcinoma (Martín-Satué and Blanco, 1999) . In corroboration with these observations, it has also been reported that both semaphorin 3 and semaphorin 6B could be detected by reverse transcription-polymerase chain reaction analysis of glioma cell lines (Correa et al., 2001; Rieger et al., 2003) .
Previous peptide sequences that target to human malignant glioma cells have been isolated (Spear et al., 2001; . However, the reported specificity is limited and confined to a single glioma cell line. Spear et al. reported a peptide, having the sequence MCPKHPLGC, that binds only to the U87MG glioma cell line (Spear et al., 2001) . Zhang et al. also reported a sequence that binds to glioma cells. However, this sequence is not glioma specific, as it also binds to other cancer cell lines . In our study, phage bearing the MG11 sequence gave a binding enrichment of more than 5-fold for glioma cells in comparison with nonglioma cells (Fig.  1) . Consistent with the in vitro data, the MG11 peptide-encoding phages were able to target specifically to dGli36 and SF767 human glioma xenografts, with a 5-fold binding enrichment over that of a nonglioma tumor xenograft under similar conditions (Fig. 2B) . Furthermore, the MG11 peptide was able to direct and confine the gene expression of the luciferase DNA specifically to human glioma cells (Fig. 3) . Currently, the lack of selectivity of cancer chemotherapeutic drugs results in high toxicities. As MG11 offers selective binding, it could potentially be useful as a targeting molecule. However, to enhance the effectiveness of targeting, the therapeutic index (ratio of binding to target glioma tissue versus binding to normal tissues) for each and every toxic molecule that may be conjugated to MG11 needs to be determined.
One of the challenges for in vivo targeting is to be able to direct the binding of the targeting peptide to tumor cells instead of normal cells. We have shown that the MG11 peptide binds only to human glioma-derived cell lines (Fig. 4) and primary human glioma cells (Fig. 5A ), but not to normal human brain cells (Fig. 5C ) or other nonglioma cells (Fig. 4) . These observations would be of great relevance in designing strategies for targeted therapy of glioma.
In summary, the identification of the MG11 sequence allows the possibility of coupling therapeutic agents directly to the peptide for targeting glioma cells. This could lower the therapeutic doses of either DNA or drugs required and would therefore reduce any potential harmful side effects resulting from the use of high doses of therapeutic agents. However, to effectively deliver DNA into cells, the uptake, intracellular trafficking, and nuclear retention of the plasmid DNA need to be achieved. Cationic lipids, viral vectors, and polymers are some of the agents that could be employed for the conjugation of peptides to enhance the in vivo stability of these peptides. Furthermore, the addition of chloroquine to cells could help to protect the targeting peptide-DNA complexes from lysosomal degradation, and could potentially enhance the effectiveness of a specific gene delivery protocol (Zauner et al., 1997) . These are some of the strategies that are being exploited in our laboratory to further enhance the capability of MG11 to function as a glioma-specific targeting molecule.
